Therefore, BRD7 may inhibit the malignant progression of breast cancer and improve the chemotherapy sensitivity of PTX by negatively regulating the activity of the YB1/Bcl-2 transcription axis, which needs further investigation. Here, BCL2 is linked to breast cancer.